Accelerate biotechnology

Meet the experts

Analytical assay development: go ALL the way

Meet the Expert: Gert, Analytical Assay Scientist The truth is; the accuracy and robustness of any process under development or manufacturing outcome is only as good as the reliability of the assays needed to understand the process. The effort involved to get to a comfortable situation where all necessary tests are available, is often highly…


Latest advancements in bioprocess intensification for efficient biopharmaceutical production

Meet the Expert: Ahd, Bioprocess Project Director Current costs of biopharmaceutical manufacturing often prevent segments of the world’s population from accessing critical medicines or even prevent medicines from being marketed. A significant part of these costs come from the need for large and expensive manufacturing facilities. This hurdle can be overcome by significantly intensifying the…


Select your protein expressing cell line: first time right

Meet the Expert: Sagrario, R&D Program Manager The selection of stable protein producing cell lines is a tedious process in which normally two substantially different approaches are being pursued in the field. One strategy relies on robot-assisted, high-throughput screening of thousands of transfected expression cells, whereas the other hinges on the stringent selection of only…


Genetic stability studies: could process parameters change your virus?

Meet the Expert: Monika, Viral vector scientist Despite having very limited coding capacity, most of the RNA viruses are surprisingly good at escaping the hosts immune response and withstanding antiviral drugs. RNA viruses achieve this by virtue of their ability to multiply rapidly, coupled with their high mutation rate compared to DNA viruses. An important cause for the…


Tackling the capacity bottleneck in downstream processing of viral vectors

Meet the Expert: Paddy, DSP scientist With the first gene therapies now being on the market, the production quantities for gene therapy vectors are increasing to satisfy the demand. A steady increase of product titers and the corresponding change in impurity composition represent a challenge for development and optimization of viral vector production processes. The…


In manufacturing it’s ALL about Quality Control

Meet the Expert: Freek, Quality Control / Validation Scientist The Quality Control (QC) department performs analytical development, assay qualification, assay validation, testing on raw materials, cell substrates and cell banks. Also, the department is heavily involved in the “in-process” testing as well as testing the final drug substance and drug product. In addition, QC ensures…


Drivers in selecting a reliable partner for clinical GMP manufacturing

Meet the Expert: Pim, GMP Scientist One of the most sought-after outsourcing demands in life sciences is clinical GMP manufacturing and release of biopharmaceutical products to allow subsequent testing in human subjects for safety and efficacy. Globally the market for this outsourcing activity is estimated at about $3 billion annually, of which about 85% is…


Quality specialist is key in any biopharmaceutical development team

Meet the Expert: Margreet, QA specialist The ability to translate biopharmaceutical research into products is known to have a high failure rate. A staggering 75% of published pre-clinical data cannot be reproduced or validated to allow further product development1. I believe that the only way to prevent such disappointments both scientifically, as well as commercially,…


The E. coli platform for production of therapeutic antibody fragments

Meet the Expert: Pranav, Microbial Bioprocess Scientist E. coli has been used as a platform for the production of therapeutic proteins since the late 1970’s. The organism is a well-known and cost-effective biological production factory for which many genetic tools and scale up cultivation strategies are available. As a matter of fact, around 30% of…


The need to increase production yield of therapeutic proteins

Meet the Expert: Abhinav, Principal Scientist. Biopharmaceuticals are expensive due to the many years of research and development associated with the discovery, development, clinical testing, and market launch of these medicines. As an example; the Food and Drug Administration (FDA) approved a monoclonal antibody called ipilimumab (Yervoy; Bristol-Myers Squibb, New York, NY) for the treatment…